Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis

Clinical Microbiology and Infection

Volumn 14, Issue 8, 2008, Pages 801-805

  Bébéar, Cecile M ^a   De Barbeyrac, B ^a   Pereyre, S ^a   Renaudin, H ^a   Clerc, M ^a   Bebear C ^a  

^a Univ Victor Segalen Bordeaux 2   (France)

Author keywords

Chlamydia trachomatis; Fluoroquinolones; Moxifloxacin; Urogenital mycoplasmas

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH DILUTION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; NONHUMAN; PRIORITY JOURNAL; UREAPLASMA; UROGENITAL TRACT INFECTION;

CHLAMYDIA TRACHOMATIS; MYCOPLASMA; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMATALES; UREAPLASMA;

EID: 48449091761     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02027.x     Document Type: Article

References (14)

1. Waites KB, Crabb DM, Bing X et al. In.vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003; 47: 161-165.
2. Pereyre S, Renaudin H, Bébéar C et al. In.vitro activities of newer quinolones, garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob Agents Chemother 2004; 48: 3165-3168.
3. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and fluoroquinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.
4. Bébéar CM, Renaudin H, Boudjadja A et al. In.vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob Agents Chemother 1998; 42: 703-704.
5. Donati M, Rodriguez Fermepin M, Olmo A et al. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother 1999; 43: 825-827.
6. Malay S, Roblin PM, Reznik T et al. In.vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2002; 46: 517-518.
7. Woodcock JM, Andrews JM, Boswell FJ et al. In.vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-106.
8. Yi J, Yoon BH, Kim EC. Detection and biovar discrimination of Ureaplasma urealyticum by real-time PCR. Mol Cell Probes 2005; 19: 255-260.
9. Bébéar CM, Renaudin H, Charron A et al. DNA gyrase and topoisomerase. IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother 2003; 47: 3323-3325.
10. Hamasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5′ nuclease real-time PCR. Antimicrob Agents Chemother 2005; 49: 4993-4998.
11. Waites KB, Bébéar CM, Roberston JA, Talkington DF, Kenny GE eds. Cumitech 34, Laboratory diagnosis of mycoplasmal infections. Washington, DC: ASM Press, 2001.
12. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003; 47: 636-642.
13. Poutiers F, de Barbeyrac B, Garcia-Mace J et al. In vitro activity of a new quinolone, NM 394, against Chlamydia trachomatis. Pathol Biol 1996; 44: 351-354.
14. Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis 2006; 12: 1149-1152.